Abstract
A 51-year-old female patient in the first chronic phase of CML received an allogeneic PBSCT from a matched unrelated donor. The transplant was manipulated by CD34+ cell selection. On day +193 after transplantation the patient was readmitted to the hospital with recurrent fever of unknown origin and cough. Clinical, radiographic and sonographic evaluation revealed no characteristic findings besides a mild splenomegaly. Screening for EBV, CMV, RSV and HSV did not indicate an active infection. On day +203 the patient developed generalized seizures, respiratory failure and died within 24 h in multiorgan failure. The macroscopic postmortem was still not enlightening; the histological examination however, demonstrated diffuse organ infiltration by monoclonal lymphoblastoid cells due to EBV-LPD. Bone Marrow Transplantation (2001) 28, 615–618.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hanto W . Classification of Epstein–Barr virus-associated post-transplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies Annu Rev Med 1995 46: 381–394
Shapiro RS, McClain K, Frizzera G et al. Epstein–Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation Blood 1988 71: 1234–1243
Rooney CM, Smith CA, Ng CYC et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients Blood 1998 92: 1549–1555
Papadopolous EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein–Barr virus lymphoproliferative disorders after allogeneic bone marrow transplantation New Engl J Med 1994 330: 1185–1191
Kuehnle I, Huls MH, Liu Z et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoetic stem-cell transplantation Blood 2000 95: 1502–1505
Rooney CM, Loftin SKI, Holladay MS et al. Early identification of Epstein–Barr virus associated post-transplantation lymphoproliferative disease Br J Haematol 1995 89: 98–103
Hoshino Y, Kimura H, Kazushimi K et al. Early intervention in post-transplant lymphoproliferative disorders based on Epstein–Barr viral load Bone Marrow Transplant 2000 26: 199–201
Cohen JI . Epstein–Barr virus infection New Engl J Med 2000 343: 481–492
Hale G, Waldmann H . Risks of developing Epstein–Barr virus-related lymphoproliferative disorder after T cell-depleted marrow transplants Blood 1998 91: 3079–3083
Cavazzana-Calvo M, Bensoussan D, Jabado N et al. Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation Br J Haematol 1998 103: 543–551
Caldas C, Ambinder R . Epstein–Barr virus and bone marrow transplantation Curr Opin Oncol 1995 7: 102–106
Ramasamy I, Brisco M, Morley A . Improved PCR method for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell neoplasms J Clin Pathol 1992 45: 770–775
Acknowledgements
Special thanks to F Leithäuser for the analysis of the IgH gene rearrangement.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ringhoffer, M., Döhner, K., Scheil, S. et al. Fatal outcome in a patient developing Epstein–Barr virus-associated lymphoproliferative disorder (EBV-LPD) without measurable disease. Bone Marrow Transplant 28, 615–618 (2001). https://doi.org/10.1038/sj.bmt.1703188
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703188
